SG11201807474SA - Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies - Google Patents

Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies

Info

Publication number
SG11201807474SA
SG11201807474SA SG11201807474SA SG11201807474SA SG11201807474SA SG 11201807474S A SG11201807474S A SG 11201807474SA SG 11201807474S A SG11201807474S A SG 11201807474SA SG 11201807474S A SG11201807474S A SG 11201807474SA SG 11201807474S A SG11201807474S A SG 11201807474SA
Authority
SG
Singapore
Prior art keywords
medimmune
international
gaithersburg
llc
rule
Prior art date
Application number
SG11201807474SA
Other languages
English (en)
Inventor
Jiali Du
Ambarish Shah
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201807474SA publication Critical patent/SG11201807474SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201807474SA 2016-04-25 2017-04-24 Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies SG11201807474SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662327214P 2016-04-25 2016-04-25
PCT/US2017/029143 WO2017189433A1 (en) 2016-04-25 2017-04-24 Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies

Publications (1)

Publication Number Publication Date
SG11201807474SA true SG11201807474SA (en) 2018-11-29

Family

ID=60089975

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807474SA SG11201807474SA (en) 2016-04-25 2017-04-24 Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies

Country Status (19)

Country Link
US (2) US10421811B2 (es)
EP (1) EP3448428A4 (es)
JP (1) JP2019514889A (es)
KR (1) KR20180135475A (es)
CN (1) CN109069631A (es)
AR (1) AR108317A1 (es)
AU (1) AU2017257505B2 (es)
BR (1) BR112018071287A2 (es)
CA (1) CA3020893A1 (es)
CL (1) CL2018002998A1 (es)
CO (1) CO2018011195A2 (es)
IL (1) IL262344A (es)
MA (1) MA44783A (es)
MX (1) MX2018012651A (es)
RU (1) RU2018140960A (es)
SG (1) SG11201807474SA (es)
TW (1) TW201740976A (es)
WO (1) WO2017189433A1 (es)
ZA (1) ZA201807888B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210143932A (ko) * 2013-09-11 2021-11-29 메디뮨 리미티드 종양 치료용 항-ｂ7-ｈ1 항체
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
GEP20217328B (en) 2015-12-14 2021-12-10 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
AU2017284632B2 (en) 2016-06-13 2020-05-14 I-Mab Biopharma Co., Ltd. Anti-PD-L1 antibodies and uses thereof
EA201991870A1 (ru) * 2017-02-16 2020-02-12 МЕДИММЬЮН, ЭлЭлСи Лечение рака мочевого пузыря с помощью антитела к pd-l1
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
KR20200021474A (ko) 2017-06-01 2020-02-28 컴퓨젠 엘티디. 삼중 조합 항체 치료제
EP3784279A1 (en) * 2018-04-25 2021-03-03 MedImmune Limited Formulations of human anti-pd-l1 antibodies
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
CA3203441A1 (en) * 2020-12-30 2022-07-07 Jing Zhu Formulations of anti-cd73 antibodies
WO2024094831A1 (en) * 2022-11-04 2024-05-10 Astrazeneca Ab Anti-ctla antibody compositions and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871806A2 (en) * 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP4169951A1 (en) * 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CN104961829B (zh) * 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
KR20120130757A (ko) * 2010-02-26 2012-12-03 노보 노르디스크 에이/에스 안정한 항체 함유 조성물
JP2015502397A (ja) * 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
CA2923859C (en) * 2013-09-11 2021-11-23 Arsia Therapeutics, Inc. Liquid protein formulations containing viscosity-lowering agents
GB2531094A (en) * 2014-05-13 2016-04-13 Medimmune Ltd Anti-B7-H1 and Anti-CTLA-4 antibodies for treating non-small cell lung cancer
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
CA2965034C (en) * 2014-10-24 2023-05-02 Astrazeneca Ab Combination of an immunomodulatory agent and an antisense oligonucleotide
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia

Also Published As

Publication number Publication date
CO2018011195A2 (es) 2018-10-31
CN109069631A (zh) 2018-12-21
RU2018140960A (ru) 2020-05-26
AU2017257505B2 (en) 2020-05-14
MA44783A (fr) 2019-03-06
CA3020893A1 (en) 2017-11-02
CL2018002998A1 (es) 2018-12-07
ZA201807888B (en) 2019-08-28
AR108317A1 (es) 2018-08-08
EP3448428A4 (en) 2019-11-27
IL262344A (en) 2018-11-29
AU2017257505A1 (en) 2018-12-06
JP2019514889A (ja) 2019-06-06
WO2017189433A1 (en) 2017-11-02
MX2018012651A (es) 2019-01-30
US20170306025A1 (en) 2017-10-26
US20190382494A1 (en) 2019-12-19
TW201740976A (zh) 2017-12-01
EP3448428A1 (en) 2019-03-06
US10421811B2 (en) 2019-09-24
KR20180135475A (ko) 2018-12-20
RU2018140960A3 (es) 2020-08-03
BR112018071287A2 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201804969PA (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804694SA (en) Dual controls for therapeutic cell activation or elimination
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201810602YA (en) Method of treating liver fibrosis
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11202000055PA (en) Antibodies that modulate a biological activity expressed by a cell
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201900634VA (en) Chimeric antigen receptor
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201901995TA (en) Crystalline and salt forms of ppar agonist compounds
SG11201805001UA (en) Method of treating influenza a
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201407800SA (en) Selective binding of biological targets to solid phase ureides